We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
lnSphero Launches 3D InSight™ Pancreatic Microislets for Diabetes, Toxicity Research
Product News

lnSphero Launches 3D InSight™ Pancreatic Microislets for Diabetes, Toxicity Research

lnSphero Launches 3D InSight™ Pancreatic Microislets for Diabetes, Toxicity Research
Product News

lnSphero Launches 3D InSight™ Pancreatic Microislets for Diabetes, Toxicity Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "lnSphero Launches 3D InSight™ Pancreatic Microislets for Diabetes, Toxicity Research "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

lnSphero AG today announced the launch of 3D InSight™ Human and Rat Pancreatic Microislets, further expanding the company's catalog of organotypic 3D models produced using their patented hanging-drop production technology. The product launch follows lnSphero's April publication of the microislets in the Journal of Tissue Engineering and Regenerative Medicine, characterizing their physiological properties and potential for use in islet transplantation, as well as a convenient in vitro model system for drug development and toxicity studies. Primary human and rat pancreatic islets are widely used as in vitro models for diabetes and metabolic disorders, but current harvesting and isolation methods result in tissue impurities, size heterogeneity, and damage to cells that negatively impact the robustness of data generated, and hinder their use as a high-throughput tool for drug discovery.

3D InSight™ Pancreatic Microislets solve the two major shortcomings of current methods used to isolate primary human or rat pancreatic tissue: inconsistent microislet size and heterogeneous cellular composition, both of which contribute to variations in data. Controlling size is very important, says Dr. Wolfgang Moritz, co-author of the publication and co-founder of lnSphero: "As far as microislets are concerned, bigger is not better. Smaller microislets produce more insulin per cell than larger ones, and are subject to less oxidative stress during long-term culture." Typically small islets must be tediously hand-picked for in vitro studies, a process that also wastes a lot of the donor material. "We've standardized the process and dramatically reduced waste by first dissociating the tissue and then allowing a defined number of cells to reassemble in the hanging drop platform. This results in "pseudo-islets" of remarkably consistent size, which is extremely important for cell viability, functionality, and to obtain the desired well-to-well consistency required for high-throughput applications."

The cellular composition of each microislet tissue is also critical to ensuring their metabolic activity reflects that of native pancreatic islets. The lnSphero process results in microislets with a more uniform ratio of alpha, beta, and delta cells, the cells of the pancreas responsible for production of glucagon, insulin, and somatostatin, respectively. States Dr. Moritz, "3D InSight™ Pancreatic Microislets display glucose-responsive production of insulin for up to four weeks in culture, giving the researcher a metabolically active model suitable for long-term, repeat-dose efficacy and toxicity studies. The consistent size, more homogeneous cell composition, and automation-compatible format has generated significant demand for the islets for studies ranging from anti-diabetic drug efficacy to assessment of endocrine pancreatic toxicity."
Advertisement